PSILOCYBIN ADVISORY BOARD
SB2772 creates the Illinois Psilocybin Advisory Board Act, establishing a temporary advisory board within the Department of Financial and Professional Regulation to study psilocybin and related psychedelic policy. The bill’s findings cite emerging research on psilocybin for treatment-resistant depression, anxiety, PTSD, substance use disorder, headache disorders, and end-of-life distress, and note federal FDA breakthrough therapy designation for psilocybin in depression. It also references Illinois’ existing veteran-focused breakthrough therapy program and frames the measure as part of a broader move away from criminalization toward evidence-based regulation and harm reduction.
The Board is tasked with reviewing laws and regulatory models from Oregon, Colorado, and other jurisdictions; examining federal law and scientific research; and evaluating issues such as public health and safety, facilitator training, client screening and consent, service-center standards, cultural responsibility, Indigenous reciprocity, and potential insurance or Medicaid coverage. The Board must submit a report to the Governor and General Assembly within 18 months with recommendations on whether Illinois should legalize psilocybin for administration sessions and, if so, what rules should govern the program. The Act is temporary and repeals itself two years after its effective date.
The bill does not directly legalize psilocybin or amend the Illinois Controlled Substances Act in this text; instead, it creates a new advisory structure inside state government to study and recommend future policy. It would require the Department of Financial and Professional Regulation to support the Board, and it directs multiple state agencies to consider the Board’s eventual recommendations on public health, regulation, insurance, Medicaid, and possible therapeutic access. The Act would also formally define terms such as psilocybin product, facilitator, client, and administration session, laying groundwork for a regulated psilocybin services framework if later adopted.
The bill’s tone is generally supportive and exploratory, with the findings emphasizing medical research, veteran mental health, harm reduction, and equitable access. The structure of the Board and its reporting duties suggest a cautious, study-first approach rather than immediate legalization. No committee transcripts or recorded votes were provided, so there is no documented floor or committee sentiment in the supplied materials beyond the bill’s own pro-research and pro-regulation framing.
The main points of contention implied by the bill are the legalization of a controlled psychedelic substance, the safety of administration sessions, and how to regulate training, screening, and service standards. The bill anticipates concerns about contraindications, crisis response, touch boundaries, and public health safeguards, indicating likely debate over patient safety and professional oversight. It also addresses culturally sensitive issues such as Indigenous reciprocity and the impact on natural psilocybin, suggesting possible tension between commercialization, conservation, and cultural stewardship. Because no transcripts or votes are included, no specific legislators or stakeholder groups are identified as opposing or supporting these issues in the record provided.